{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-23-000045","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.705717+00:00","generated_at":"2026-06-16T03:46:03.105288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nautilus Biotech Q1 net loss $15M, cash $302M; platform launch mid-2024","bullets":["Net loss $15.0M vs $15.8M year ago; operating expenses $18.1M, up 13% YoY on higher headcount.","Cash, equivalents and investments $302.0M as of March 31, 2023; runway expected into 2025.","Platform (instruments, reagents, software) launch planned for mid-2024.","Granted 4 new US patents in Q1, raising total to 12 granted patents.","Announced three winners of First Access Challenge for Early Access Program."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-23-000045","json":"https://secwatch.observer/filing/0001808805-23-000045.json","markdown":"https://secwatch.observer/filing/0001808805-23-000045.md","text":"https://secwatch.observer/filing/0001808805-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/0001808805-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/naut-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:46:03.105288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09f380f2de076dc25f29045895982b217caf4d4a","claim":"Nautilus Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $15.0 million.","evidence_excerpt":"Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/0001808805-23-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $15.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}